An Open-label Randomized Two-arm Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of Oral BAY 1217389 in Combination With Weekly Intravenous Paclitaxel Given in an Intermittent Dosing Schedule in Subjects With Advanced Malignancies
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 10 Apr 2018
At a glance
- Drugs BAY 1217389 (Primary) ; Paclitaxel
- Indications Breast cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bayer
- 07 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 12 Dec 2017 Planned End Date changed from 23 Feb 2018 to 24 Aug 2018.
- 08 Sep 2017 Planned primary completion date changed from 27 Oct 2017 to 24 Nov 2017.